Spironolactone
| Evidence Level: L5 | Predicted Indications: 53 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Spironolactone |
| DrugBank ID | DB00421 |
| Brand Names (EU) | Qaialdo |
| Evidence Level | L5 |
| Predicted Indications | 53 |
| Top Prediction Score | 99.26% |
Approved Indication (EMA)
In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | hypotrichosis simplex of the scalp | 99.26% | DL |
| 2 | congenital hypotrichosis milia | 99.04% | DL |
| 3 | diffuse alopecia areata | 98.41% | DL |
| 4 | alopecia | 97.83% | DL |
| 5 | hypertensive disorder | 97.75% | DL |
| 6 | malignant hypertensive renal disease | 97.54% | DL |
| 7 | malignant renovascular hypertension | 97.54% | DL |
| 8 | pulmonary hypertension owing to lung disease and/or hypoxia | 97.33% | DL |
| 9 | pulmonary hypertension with unclear multifactorial mechanism | 97.33% | DL |
| 10 | Braddock syndrome | 96.64% | DL |
| 11 | chronic pulmonary heart disease | 95.55% | DL |
| 12 | Waterhouse-Friderichsen syndrome | 85.58% | DL |
| 13 | primary hereditary glaucoma | 84.05% | DL |
| 14 | acute pulmonary heart disease | 81.18% | DL |
| 15 | pregnancy associated osteoporosis | 78.56% | DL |
| 16 | Worth syndrome | 75.84% | DL |
| 17 | autosomal dominant neovascular inflammatory vitreoretinopathy | 75.68% | DL |
| 18 | open-angle glaucoma | 74.40% | DL |
| 19 | congestive heart failure | 74.04% | DL |
| 20 | postmenopausal osteoporosis | 73.28% | DL |
Showing top 20 of 53 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.